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Abstract The research focuses on the development and
optimization of ifosfamide nanostructured lipid carriers for
oral delivery with the application of response surface
methodology. The objectives of the study were to develop
a formulation for ifosfamide to be delivered orally, over-
come the instability of the drug in acidic environment
during oral administration, to sustain the release, drug
leakage during storage and low loading capacity. A mod-
ified solvent diffusion method in aqueous system was ap-
plied to prepare nanostructured lipid nanoparticles.
Hydrophilic polymers such as chitosan and sodium alginate
were used as coating materials. Glycerol mono oleate and
oleic acid were used as solid and liquid lipid, respectively.
Poloxamer is used as stabilizers. The central composite
rotatable design consisting of three-factored factorial de-
sign with three levels was used in this study. The physio-
chemical characterization included evaluation of surface
morphology, particle size and surface charge of the drug in
the delivery system. The in vitro drug release, entrapment
and drug loading efficiency and as well as the storage
stability were evaluated. The results showed that the opti-
mal formulation was composed of drug/lipid ratio of 1:3,
organic/aqueous phase ratio of 1:10 and concentration of
surfactant of 1 % w/v. Ifosfamide nanostructured lipid
carrier under the optimized conditions gave rise to the
entrapment efficiency of 77 %, drug loading of 6.14 %,
mean diameter of 223 nm and zeta potential value of
-25 mV. Transmission electron microscopy analysis
showed spherical particles. The in vitro experiment proved
that ifosfamide from the delivery system released gradually
over the period of 72 h. Sodium alginate cross-linked
chitosan nanostructured lipid carrier demonstrated en-
hanced stability of ifosfamide, high entrapment efficiency
and sustained release.
Keywords Ifosfamide  Nanostructured lipid carriers 
Oral delivery  Response surface methodology  Solvent
diffusion technique  Sustained release
Introduction
Ifosfamide is one of the widely used antineoplastic drugs
belonging to the alkylating agents group. Ifosfamide is
chemically 3-(2-chloroethyl)-2-[(2-chloroethyl) amino]-te-
trahydro-2H-1,3,2-oxazophosphorin-2-oxide. Ifosfamide is
a white crystalline hygroscopic powder having a melting
point of 40 C. The powder has a water solubility of about
100 mg/ml. Ifosfamide is used in the treatment of a variety
of solid tumors including those of the cervix, endometrium,
lung, ovary, testes and thymus as well as in sarcoma and in
the treatment of Burkitt’s lymphoma. Ifosfamide, being
susceptible to hydrolytic degradation degrades in acidic
media with its rate of degradation depending on the pH of
the solution; it is commercially available in dry form and is
supplied as sterile packaged dry powder for dissolution in
water for injection prior to administration. However, the
low melting point and the hygroscopic nature of ifosfamide
make it necessary to fill the powder with great care by
accurately controlling both temperature and humidity to
achieve a sterile product. Further, prolonged storage of the
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in turn leads to a reduction in dissolution rate, thereby
increasing the time required for reconstitution (Alexander
et al. 1993).
There is a need for an oral dosage form which elim-
inates the issues associated with the drug. Oral delivery of
Ifosfamide could provide better means and its success is
expected to revolutionize cancer chemotherapy. Oral de-
livery can maintain an optimum concentration of drug in
circulation which can provide prolonged exposure to
cancerous cells, which will in turn improve the efficacy
and decrease the adverse effects. Oral administration of
Ifosfamide would be pleasant for the patient and would no
longer constitute a risk for the medical personnel. Hence,
it was sought to develop an oral delivery system that
could stabilize Ifosfamide in acidic environment and re-
duce the formation of the toxic metabolites by preventing
its exposure to the acidic medium. NLCs of ifosfamide
could sustain the release of, as well as overcome the in-
stability of the drug in acidic environment during oral
administration.
Lipids and lipid nanoparticles are extensively employed
as oral-delivery systems for drugs and other active ingre-
dients. Lipids usually enhance drug absorption in the gas-
trointestinal tract (GIT), and when formulated as
nanoparticles, these molecules improve mucosal adhesion
due to small particle size and increasing GIT residence
time. In addition, lipid nanoparticles may also protect the
loaded drugs from chemical and enzymatic degradation
and gradually release drug molecules from the lipid matrix
into blood, resulting in improved therapeutic profiles
compared to free drug. Therefore, due to their phys-
iological and biodegradable properties, lipid molecules
may decrease adverse side effects and chronic toxicity of
the drug-delivery systems when compared to other of
polymeric nature.
Preparation of solid lipid nanoparticles (SLNs) is one of
the approaches used to encapsulate hydrophilic drugs to
obtain good sustained release and better entrapment effi-
ciency. But, the common disadvantages experienced with
solid lipid nanoparticles are particles growing, unpre-
dictable gelation tendency, unexpected dynamics of poly-
morphic transitions and inherent low incorporation rate due
to the crystalline structure of the solid lipid (Das and
Chaudhury 2011; Muller et al. 2002a, b; Selvamuthukumar
and Velmurugan 2012). In general, drug molecules stay in
between the fatty acid chains or as amorphous clusters in
crystal imperfections within SLN matrix. But, when lipid
transforms to low energetic form, it forms a perfect crys-
talline lattice that allows very small space for the drug
molecules. Therefore, expulsion of encapsulated drug
molecules may be observed during storage, especially
when SLN matrix is composed of a highly purified lipid,
which leads to limited drug loading capacity of SLNs.
Therefore, an amount of entrapped drug and drug release
profile of SLNs may change with storage time (Westesen
et al. 1997).
In the process of further improvement and reduction of
these drawbacks of SLN, nanostructured lipid carrier
(NLC) has been evolved as alternative drug carrier sys-
tems. NLC matrix is composed of mixture of spatially
different lipid molecules, normally mixture of solid and
liquid lipid, which leads to more imperfections in the
matrix to accommodate more drug molecules than SLN.
Despite the presence of liquid lipid, NLC matrix is solid at
room/body temperature (Chen et al. 2010). It is expected
that the drug loading capacity will be enhanced, drug ex-
pulsion during storage will be minimized due to the im-
perfect crystal lattice and drug release profile can be easily
modulated by varying the lipid matrix composition (Radtke
et al. 2005a, b).
Glycerol mono oleate is a lipid that can incorporate
large amounts of water in it and form liquid crystalline
phases. Due to this property, it has been used for sus-
tained release of Ifosfamide. A liquid lipid oleic acid has
been used, which acts act as a stabilizer for water in oil
emulsions. Poloxamer 188 was used as surfactant and
sodium alginate has been used as a crosslinking agent.
PVA is a stabilizer for (o/w) emulsions and was used in
sonication to stabilize the emulsion. Low-molecular-
weight chitosan having 85 % degree of deacetylation was
used. Low-molecular-weight and higher degree of
deacetylation are responsible for improving the solubility
of chitosan. Low-molecular-weight chitosan also helps
achieve smaller particle size and better redispersibiliy of
particles in water. Introduction of chitosan also produces
nanoparticles with positive surface charge and addition of
sodium alginate changes the surface charge to a negative
value. As Ifosfamide is a highly hydrophilic drug, it is
very difficult to prepare a nanoformulation with high
drug loading efficiency by using lipid phase alone.
Therefore, chitosan coating over nanostructured lipid
carriers will produce a well-dispersed nanoparticle with
enhanced drug loading efficiency and modified drug-re-
lease profile.
Further, the effects of drug/lipid ratio (X1), organic/
aqueous phase ratio (X2) and surfactant concentration (X3)
on the entrapment efficiency (EE), drug loading (DL)
percentage and mean particle size (PS) of IF NLC were
investigated in detail making use of central composite ro-
tatable design (CCRD) which is an ideal tool for process
optimization (Box and Hunter 1957; Kassama et al. 2008).
Model equations were derived by computer simulation
programming Design Expert 8.0.7.1 to optimize Ifos-
famide NLC. For a better understanding of the three vari-
ables, the models were presented as three-dimensional (3D)
response surface graphs.




Ifosfamide (99.0 % purity) was obtained from Sigma Aldrich
(India). Glycerol monooleate and oleic acid were purchased
frommetro labs Ltd., Chennai. Lutrol F 68 (Poloxamer 188)
was kindly gifted by BASF India Ltd. Low-molecular-weight
chitosan (MW 10000-12000 DA) was acquired from Aldrich
Chemical Co (Mumbai, India). Ethanol, acetone and other
chemicals were of analytical grade. Milli Q water (Millipore)
was used throughout the studies.
Preparation of NLC
Weighed quantities of glycerol monooleate, oleic acid and
Ifosfamide were dissolved in 5 mL of mixture of ethanol
and acetone (1:1 v/v) in a water bath at 35 C. The resul-
tant organic solution was quickly dispersed into 50 mL of
aqueous solution of Poloxamer 188 (1 % w/v) at room
temperature (25 C) under sonication for 2 min. To this
primary emulsion 6.25 mL of chitosan solution (2 % w/v)
(Chitosan solution was prepared by dissolving 2.4 g in
100 mL water containing 2 % w/v acetic acid) was added
and sonicated for 2 min. Then 10 mL of sodium alginate
solution was added under magnetic stirring for 30 min until
nano suspension was obtained. Prepared NLC was placed
into a vacuum desiccator for 24 h at room temperature to
evaporate the residual organic solvent. The final product is
placed in dry and cool place until further use (Pandit and
Dash 2011; Yuan et al. 2007; Hu et al. 2008). A schematic
representation of ifosfamide NLC preparation and
nanoparticles containing chitosan and sodium alginate is
given in Figs. 1 and 2, respectively.
Experimental design
Preliminary experiments indicated that the variables, such
as a ratio between the drug and lipid concentration, a ratio
of organic/aqueous phase volume and the concentration of
surfactant were the main factors that affected the particle
size, drug loading and entrapment efficiency of nanopar-
ticles. Thus, a central composite rotatable design-response
surface methodology (CCRD-RSM) was used to sys-
temically investigate the influence of these three critical
formulation variables on particle size, drug loading and
entrapment efficiency of the prepared NLC. The details of
the design are listed in the Table 1. For each factor, the
experimental range was selected based on the results of
preliminary experiments and the feasibility of preparing the
NLC at the extreme values. The range of values for vari-
ables was selected as follows:
Drug/lipid ratio (X1)—1:3–1:7
Organic/aqueous phase ratio (X2)—1:5–1:15
Surfactant concentration (X3)—0.25–1 %.
With the use of three factors to be studied, CCRD-RSM
suggests a total of 20 experiments to be carried out. All the
formulations in these experiments were prepared in
duplicate.
HPLC assay method for Ifosfamide
The HPLC separation of Ifosfamide was achieved using
C18 column (250 9 4.6 mm, 5 l; Phenomenex). The
mobile phase consisted of water: acetonitrile (70:30 v/v).
The flow rate was maintained at 1.5 mL/min and the col-
umn was maintained at 40 C. The column effluents were
monitored at 195 nm and quantified using area under the
peak for the unknown drug and compared with area under
the peak for the standard solutions prepared in the mobile
phase (Pandit and Dash 2011).
Characterisation
Particle size, polydispersity index and zeta potential
measurement
Particle size and polydispersity indices of NLC formula-
tions were measured by dynamic light scattering using a 90
plus particle sizer (Master sizer, Malvern instruments)
equipped with MAS OPTION particle sizing software. The
measurements were made at a fixed angle of 90 for all
samples. The samples were suitably diluted with Milli Q
water for every measurement. Zeta potential measurements
were also made using an additional electrode in the same
instrument. For zeta potential determination, samples of all
formulations were diluted with 0.1 mM KCl and placed in
the electrophoretic cell, where an electric field of about
15 V/cm was applied. The mean hydrodynamic diameter
(Dh) and polydispersity index (PI) of the particles were
calculated using the cumulative analysis after averaging the
three measurements.
Transmission electron microscopy
Transmission electron microscopy (TEM) was performed
using a Philips CM 10 transmission electron microscope.
The sample was prepared by a formvar resin grid method.
Briefly, a 0.5 % w/v suspension of NLC was sprayed on a
formvar resin-coated TEM grid and air-dried for 10 min
before observation. Contrast enhancement and particle
measurement were performed using the NIH image
software.
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Determination of drug loading and entrapment efficiency
Drug encapsulation efficiency and drug loading of the pre-
pared NLCs were determined by the following procedures.
First, a certain volume of NLCs suspension was accurately
taken, dissolved and diluted with anhydrous methanol.
Then, drug content in the resultant solution was determined
by HPLC method described in item 2.4, and the calculated
drug amount was designated as Wtotal. To determine the
unencapsulated drug, equal volume of NLC suspension was
accurately taken and ultra-filtered by a filter membrane with
molecular weight cut-off (MWCO) of 12 kDa (Reili Sepa-
ration Instrument Factory, Shanghai, China). The ultra-fil-
trate was diluted with anhydrous ethanol and drug content in
Fig. 1 Schematic presentation
of Ifosfamide NLC preparation
Fig. 2 Schematic diagram of
nanoparticles containing
chitosan and sodium alginate
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the resultant solution was analyzed under the same HPLC
condition. The amount of free drug was designated asWfree.
Consequently, the drug encapsulation efficiency (EE) and
drug loading (DL) could be calculated using the following
equations (Liu and Gao 2009).
EE %ð Þ ¼ Wtotal Wfree
Wtotal
 100 ð1Þ
DL %ð Þ ¼ Wtotal Wfree
Wlipid
 100; ð2Þ
where Wtotal is the total amount of drug, Wfree is the amount
of unencapsulated drug and Wlipid, the weight of the lipid.
FT-IR spectroscopy
FTIR was performed using a Perkin Elmer system 2000
spectrophotometer to understand if there is any interaction
between the drug and excipients. The spectra were obtained
at the region 4000–400 cm-1.
Differential scanning calorimetry
The physical states of the NLCs were characterized using a
differential scanning calorimetric (DSC) thermogram ana-
lyser (STA 6000 Simultaneous Thermal Analyser, Perkin
Elmer, Waltham, MA). 6 mg of each sample (Ifosfamide,
excipients and NLCs) was sealed separately in a standard
aluminum pan, and purged with pure dry nitrogen gas set at a
flow rate of 10 mL/min, the temperature variation was set at
10 C/min and the heat flow was recorded from 0 to 350 C.
X-ray diffraction (XRD) studies
The X-ray diffraction (XRD) patterns of NLCs were de-
termined using XRD diffractometry (D8 ADVANCE,
Bruker AXS Inc, Madison, WI). The X-ray source was
high flux K-a-1 radiation from a copper target with a
graphite monochromater. The X-ray tube was operated at a
potential of 40 kV and a current of 100 mA. The range (2h)
of scans was from 0 to 50 and the scan speed was 2 per
minute at increments of 0.02. The XRD patterns of Ifos-
famide, blank nanoparticles and NLCs were obtained.
In vitro release study
The in vitro release was carried out using multi-compart-
ment rotating cells with a dialysis membrane (cut off
12,000 Da). The donor phase consisted of 2 mL of for-
mulation in phosphate buffer at pH 7.4. The receiving
phase also consisted of phosphate buffer, pH 7.4. The re-
ceiving phase was completely withdrawn and replaced with
fresh medium after fixed time intervals, suitably diluted
and analyzed using the HPLC method as described in the
Sect. 2.4. The release studies were conducted in the same
way in both pH 1.2 and pH 6.8 phosphate buffer solutions.
Stability studies
NLC formulations were stored in the sealed amber-colored
glass vials at 2–8 C and 25 C under dark environment.
The formulations were analyzed for particle size, zeta po-
tential, drug loading and encapsulation efficiency after 1, 3
and 6 months of storage and compared with formulations
made initially. In addition, the drug release study of the
NLCs stored at 2–8 C and 25 C for 6 months was per-
formed and compared with the formulations made initially.
The experiments were performed in triplicate.
Statistical analysis
The relationships between responses and formulation
variables of all model formulations were treated by Design
Expert 8.0.7.1 software. Statistical analysis, including
stepwise linear regression and response surface analysis
was conducted. The significant terms (p\ 0.05) were
chosen for final equations. Suitable models consisting of
three components include linear, quadratic and special
cubic models. The best-fitting mathematical model was
selected based upon the comparisons of several statistical
parameters, including the coefficient of variation (CV), the
multiple correlation coefficients (R2) and the adjusted
multiple correlation coefficient (adjusted R2).
Results
Optimization of formulations
The CCRD-RSM constitutes an alternative approach be-
cause it offers the possibility of investigating a high
number of variables at different levels with only a limited
number of experiments (Ahn et al. 2008). The variables in
the Table 1 were chosen taking into account our
Table 1 Independent variables and their corresponding levels of
NLC preparation for CCRD
Variables Levels
-1.682 -1 0 ?1 ?1.682
Drug/lipid ratio 1:1.64 1:3 1:5 1:7 1:8.36
Organic/aqueous phase
ratio





0.25 % 0.57 % 1 % 1.29 %
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preliminary experiments. Table 2 showed the experimental
results concerning the tested variables on entrapment effi-
ciency (EE), drug loading (DL) and particle size (PS). The
three dependent values EE, DL and PS ranged from 56 to
81 % by weight, 7–19 % by weight and 220–396 nm, re-
spectively. A mathematical relationship between factors
and parameters was generated by response surface regres-
sion analysis using Stat-Ease Design Expert 8.0.7.1
software. The three-dimensional (3D) response surface
graphs for the most statistically significant variables on the
evaluated parameters are shown in Fig. 3.
The response surface diagrams showed that the higher
the surfactant concentration the higher the EE, and the
higher the lipid concentration the higher the DL and larger
the PS. In addition, a higher ratio of aqueous phase to
organic phase resulted in higher EE, lesser DL and also
smaller PS. Furthermore, the PS significantly increased
with the increasing aqueous phase ratio indicating that the
aqueous phase ratio significantly affected the PS. It was
observed that the best fitted model was the quadratic
model, and the comparative values of R, SD and % CV
along with the regression equation generated for the se-
lected responses are given in Table 3. Only statistically
significant (p\ 0.05) coefficients are included in the
equations. A positive value represents an effect that favours
the optimization, while a negative value indicating an in-
verse relationship between the factor and the response
(Myers and Montgomery 2002). It is clear from the equa-
tion that the factor drug/lipid ratio (X1) as well as organic/
aqueous phase ratio (X2) has a negative effect and that
concentration of surfactant (X3) has a positive effect on the
response EE. The factor organic/aqueous phase ratio (X2)
and concentration of surfactant (X3) have a negative effect,
and the factor drug/lipid ratio (X1) has a positive effect on
the response DL. As far as PS is concerned, the factor drug/
lipid ratio (X1) and organic/aqueous phase ratio (X2) have a
positive effect, and the concentration of the surfactant (X3)
has a negative effect. It also shows that the relationship
between responses and factors is not always linear. Used at
different levels in an analysis or when more than one factor
is changed simultaneously, a factor can produce different
degrees of response.
Predicted optimum ranges of the independent variables
are listed in Table 4. The fitting results indicated that the
optimized NLC with high EE, high DL percentage and
small PS was obtained with the drug/lipid ratio of 1:3, or-
ganic/aqueous phase ratio of 1:10 and surfactant concen-
tration of 1 % w/v, respectively. Table 4 shows that the
experimental values of the two batches prepared within the
optimum range were very close to the predicted values, with
low percentage bias, suggesting that the optimized formu-
lation was reliable and reasonable. It can be concluded that
a high desirability value could be obtained with a drug/lipid
ratio of 1:3, organic/aqueous phase ratio of 1:10 and sur-
factant concentration of 1 % w/v.
Perturbation plots are presented in Fig. 4 for predicted
models to gain a better understanding of the investigated
procedure. These types of plots show the effect of an in-
dependent factor on a specific response, with all other
factors held constant at a reference point (Myers and
Montgomery 1995). A steepest slope or curvature indicates
sensitiveness of the response to a specific factor. Figure 4a
shows that drug/lipid ratio (Factor A) had the most im-
portant effect on EE followed by Factor B and C. Figure 4b
shows that organic/aqueous phase ratio (Factor B) had the
most important effect on DL followed by factor C and then
A. Figure 4c shows that concentration of surfactant (Factor
C) had the most important effect on particle size followed
by factor A and then B.
Characterization
Particle size, polydispersity index and zeta potential
measurement
The mean particle size of NLC was 223 nm with a poly-
dispersity index of 0.194 ± 0.025. A narrow PI means that
the colloidal suspensions are homogenous in nature. The
Table 2 Central composite design consisting of experiments for the
study of three experimental factors in coded levels with experimental
results
Formulation Coded value variables Response values
X1 X2 X3 EE (%) DL (%) PS (nm)
1 -1 -1 -1 70.2 13.2 283.3
2 ?1 -1 -1 68.3 19.2 295.2
3 -1 ?1 -1 62.1 10.3 315.2
4 ?1 ?1 -1 56.2 14.5 350.4
5 -1 -1 ?1 71.3 11.2 285.6
6 ?1 -1 ?1 73.4 17.1 310.4
7 -1 ?1 ?1 81.2 9.2 310.2
8 ?1 ?1 ?1 73.1 14.3 339.3
9 -1.682 0 0 69.3 7.6 335.2
10 ?1.682 0 0 60.2 18.5 396.8
11 0 -1.682 0 66.4 17.7 385.6
12 0 ?1.682 0 69.3 11.4 380.6
13 0 0 -1.682 64.2 13.1 265.4
14 0 0 1.682 74.6 12.8 220.2
15 0 0 0 67.8 13.9 325.4
16 0 0 0 67.2 14.6 325.8
17 0 0 0 67.9 14.8 325.2
18 0 0 0 67.1 14.2 325.4
19 0 0 0 67.3 14.4 325.4
20 0 0 0 67.4 14.2 325.8
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zeta potential of the NLC was found to be -25 mV, and it
is sufficiently high to form stable colloidal nanosuspension.
Transmission electron microscopy
In order to provide information on the morphology and
size of the optimal Ifosfamide NLC, TEM was used to
take photos of the optimal NLC formulation, as shown
in Fig. 5. The NLC particles are spherical. The size of
the NLC is about 200 nm. The diameter observed by
TEM is smaller, while the diameter determined by DLS
is above 223 nm. The reason may be that the two
methods are based on different sample preparation
processes.
Fig. 3 Three-dimensional (3D) response surface plots showing the
effect of the variable on response. a The effect of organic/aqueous
phase ratio and surfactant concentration on the entrapment efficiency;
b the effect of drug/lipid ratio and organic/aqueous phase ratio on the
drug loading; c the effect of organic/aqueous phase ratio and
surfactant concentration on the drug loading; d the effect of drug/
lipid ratio and organic/aqueous phase ratio on the particle size
Table 3 Reduced response models and statistical parameters obtained from ANOVA
Responses Regression models Adjusted R2 Model P value %CV Adequate precision
Entrapment
efficiency
67.45 - 1.77X1 - 0.88X2 ? 3.65X3 ? 2.88X2X3 0.8126 0.0001 3.28 21.28
Drug loading 14.06 ? 2.89X1 - 1.69X2 - 0.49X3 - 0.37X1X2
? 0.37X2X3 - 0.45X1
2 -0.45X3
2
0.8563 0.0001 2.86 10.42





0.8824 0.0001 3.12 14.26
Acceptance criteria C0.80 \0.05 \4 [10 %
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Fourier transform infrared spectroscopy (FTIR)
The FTIR spectra for chitosan, cross-linked chitosan
particles with IF, are shown in Fig. 6. Cross-linked drug
loaded particles show a peak for P=O bond at 1113 cm-1.
Sodium alginate gives a characteristic peak at 1624 cm-1,
which shifts to 1651 cm-1in cross-linked particles, and a
new peak appears at 1736 cm-1 after cross-linking with
chitosan. A strong band occurs in the region from 3200 to
3500 cm-1, which becomes very strong in the cross-
Table 4 Comparison of experimental and predicted values under optimal conditions for final formulation
Drug lipid ratio Organic aqueous phase ratio Surfactant concentration Particle size (nm) % Entrapment efficiency % Drug loading
1:3 1:10 1 %
Predicted 220 79 7.24
Experimental 223 77 6.14
Bias (%) 3 % 4 % 1 %
Acceptance criteria = 6 %
Bias was calculated as (predicted value - experimental value)/predicted value 9 100
Fig. 4 Perturbation plots showing the effect of each of the independent variables on a entrapment efficiency, b drug loading and c particle size,
where A, B and C are drug/lipid ratio, organic/aqueous phase ratio and concentration of surfactant, respectively
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linked particles. Peaks at 2924 and 2876 cm-1were also
noticed.
Differential scanning calorimetry
The DSC analysis was performed for the Ifosfamide, chi-
tosan, sodium alginate, glycerol monooleate and the Ifos-
famide formulation to found out the physical state of the
drug inside the nanoparticulate formulation. DSC gives a
measure of the change in enthalpy. DSC was used to un-
derstand the holistic picture of true encapsulation. From
Fig. 7, it is observed that the Ifosfamide at*44 C had an
endothermic peak of melting point. These characteristic
peaks were absent in the formulation. But an endothermic
peak at*110 C was observed, due to the melting point of
the chitosan crystals. The endothermic peaks of the GMO
and sodium alginate were also absent in the final
formulation.
X-ray diffraction studies
Figure 8 depicts the comparison of XRD analysis of Ifos-
famide, blank NLCs and NLCs. The diffraction pattern
exhibited Ifosfamide had two sharp peaks at 2h = 14.78,
and 15.16 and some peaks of lower intensity. These re-
sults indicate the crystalline nature of Ifosfamide. The
diffraction characterised peaks were absent in the formu-
lation as well as in the blank nanostructured lipid carrier.
Fig. 5 TEM of Ifosfamide
nanostructured lipid carrier
a magnification 912,000 and
b magnification 946,000





















Fig. 6 FTIR of chitosan, sodium alginate, gmo, ifosfamide and ifosfamide nanostructured lipid carrier
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The in vitro release study of optimized Ifosfamide
NLC formulation
The in vitro release curve of the optimal formulation is
shown in Fig. 9. The drug release from the formulation was
noted to be only 13 and 15 % in pH 1.2 and pH 6.8
phosphate buffer, respectively (Fig. 9a, b).
The delivery system showed an initial burst release with
approximately 62 % drug being released at the end of 24 h
in pH 7.4 phosphate buffer solutions. The release of Ifos-
famide was gradual thereafter with a plateau being reached
after 70 h (Fig. 9c). Meanwhile, the drug is quickly re-
leased from conventional suspension compared with that of
NLC (Fig. 9d).
Release data of drug from the nanoformulation was well
fitted to first-order reaction, with the R2 value of 0.979 and
described as follows: log Qt = log Q0 ? Kt/2.303
Stability of Ifosfamide loaded nanostructured lipid
carrier
To investigate the effect of storage temperature on the
stability of Ifosfamide nanoformulation, the NLC suspen-
sions were stored at 2–8 C and 25 C in the dark over a
period of 180 days. An increase in particle size and de-
crease in zeta potential, drug loading and entrapment effi-
ciency were observed with storage time at both the storage
conditions are shown in Table 5. To evaluate any changes
of drug release profile during storage, drug release studies
were performed and compared with the initial formulations
depicted in Fig. 10. A marginal difference in release rate
was observed from both the formulations stored at different
storage conditions. A sustained drug release was noticed
with both the formulations stored at different storage
conditions.
Fig. 7 DSC of ifosfamide,
glycerol monooleate, chitosan,
sodium alginate and ifosfamide
nanostructured lipid carrier
Fig. 8 XRD of a ifosfamide,
b blank nanostructured lipid
carrier and c ifosfamide
nanostructured lipid carrier
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Discussion
Formulation of delivery system
The nanoparticles were prepared by solvent diffusion
technique as previously described by Yuan et al. (2007)
and Hu et al. (2008). Glycerol monooleate was used as
an internal phase (Trickler et al. 2008). Poloxamer and
sodium alginate were used as surfactant and cross linking
agents, respectively. Glycerol monooleate being a lipid
can incorporate large amount of water in it and form
liquid crystalline phase. This property has been used for
the developing sustained release formulation of both
hydrophobic and hydrophilic drugs (Boyd et al. 2006).
The purpose of using oleic acid in the preparation of the
nanoparticles was to stabilize the water in oil emulsions
(Binks and Lumsdon 2000). Low-molecular weight chi-
tosan was for slow release of Ifosfamide from the NLCs.
Chitosan has the higher degree of deacetylation, which
makes it more soluble in biological system (Sannan et al.
1976). The low-molecular-weight chitosan also helps to
achieve smaller particle size and better redispersibiliy of
particles in water (Trickler et al. 2010). The nanoparti-
cles prepared with chitosan produce positive surface
charge. However, the addition of the sodium alginate
makes the nanoparticles negatively charged, which could
improve the cellular uptake of the nanoparticles. Ifos-
famide is a highly hydrophilic drug and, therefore, a high
drug loading, using only the lipid phase, is very difficult.
Therefore, chitosan is used over nanostructured lipid
carriers to enhance the drug loading and to modify the
drug-release from these nanoparticles. The Ifosfamide
NLC was prepared using three different ratios of lipid
viz. 1:3, 1:5 and 1:7. Based on the nanoparticle recovery
and EE, the 1:3 ratio was selected as the best ratio than
the other two. The other two ratios produced low DL
which causes high drug wastage during the preparation
process and also produce larger particles. These have
been repeatedly tried for three times, for reproducibility
and for consistency.
Fig. 9 Cumulative % drug release of Ifosfamide nanostructured lipid
carrier. a% drug release at the pH 1.2, b% drug release at the pH 6.8,
c % drug release at the pH 7.4 and d Comparison of the % drug
release of Ifosfamide nanostructured lipid carrier and Ifosfamide as a
pure drug candidate
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Influence of aqueous phase volume
The ratio of oil phase and aqueous phase showed a great
impact on the EE of NLC. Figure 3a clearly shows that
increasing aqueous phase volume results in an increase in
EE. This could be due to lesser aggregation of the particles
in a larger space. Different studies have shown that the
aqueous phase volume has a paramount effect on the for-
mation of nanoparticles. In a recent study, with increased
volume of aqueous phase, increase in drug content of
particles prepared by homogenization and sonication was
observed (Budhian et al. 2007). Aqueous phase volume
beyond 10 mL was not advantageous because of lower
concentration of nanodispersion without the increase in EE.
Effect of surfactant concentration
The type of compound employed for stabilization has a
pronounced effect on PS. The mean PS was found to de-
crease sharply with an increase in concentration of Lutrol F
68 up to 1 % w/v. The higher surfactant concentration
reduces the surface tension and facilitates particle partition.
The decrease in the PS is accompanied by a rapid and
tremendous increase in the surface area. Thus, the process
of primary coverage of the newer surfaces competes with
the agglomeration of the uncovered surfaces. Hence, an
increase in the surfactant concentration in the primary
dispersion results in rapid coverage of the newly formed
particle surfaces. There was an optimum concentration,
above which an increase in surfactant concentration did not
result in a decrease in PS due to a saturation point (Reddy
et al. 2006).
The broadness of the size distribution observed at higher
surfactant concentrations could be due to the higher vis-
cosity of the continuous phase which disperses the stirring
energy (Song et al. 2008). Thus, the PI value increased with
increasing surfactant concentrations. Stability (high ZP
either positive or negative) increased with increasing con-
centrations of surfactant. Thus, higher stability was ob-
served with formulations having 1 % w/v surfactant. An
increase in concentration of surfactant resulted in a slight
increase in EE and DL, as shown in Fig. 3a and c.
Influence of drug/lipid matrix ratio
Increase in matrix content is expected to raise the EE by
providing more space to incorporate the drug. Increment of
the lipid content also reduces the escaping of drug into the
external phase, which accounts for an increase in EE (Shah
et al. 2007). EE significantly increased at drug: lipid ratio
increasing from 1:3 to 1:7, whereas with this increasing
ratio, an increase in PS was observed. Numerous studies
have reported that increasing lipid content results in larger
Table 5 Particle size, zeta potential, entrapment efficiency and drug
loading capacity of ifosfamide-loaded NLCs stored at 2–8 C and
25 C over a period of 6 months
Samples 2–8 C 25 C
PS (nm)
Initial 223.2 ± 0.1 223.2 ± 0.1
3 months 228.2 ± 0.5 230.9 ± 0.3
6 months 230.9 ± 0.1 237.3 ± 0.4
ZP (-mV)
Initial 25.7 ± 2.6 25.7 ± 2.6
3 months 23.6 ± 3.8 23.5 ± 2.7
6 months 21.9 ± 2.6 20.5 ± 2.4
EE (%)
Initial 81.7 ± 1.4 81.7 ± 1.5
3 months 80.3 ± 1.3 78.1 ± 1.4
6 months 78.6 ± 1.2 74.8 ± 1.8
DL (%)
Initial 7.2 ± 0.2 7.2 ± 0.2
3 months 7.6 ± 0.1 7.5 ± 0.2
6 months 7.6 ± 0.1 7.5 ± 0.1
Fig. 10 Comparison of drug release from initial and 6-month-old NLC stored at a 2–8 C and b 25 C. Data represent mean ± SD (n = 3)
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particles and broader PS distribution (Trotta et al. 2003;
Mehnert and Mader 2001; Battaglia et al. 2007). Larger PS
with an increase in lipid content could be attributed to
decrease in emulsifying efficiency and increase in particle
agglomeration and increased DL as well, as shown in
Fig. 3b and d.
Morphological characterization
Particle size and zeta potential
Chitosan, when dissolved in acidic medium, bears a net
positive charge due to protonation of free amino groups.
On addition of sodium alginate, the protonated amino
groups of chitosan interact with –OR groups provided by
sodium alginate. The hydroxyl ions are ionically bonded
to the amino groups, which causes deprotonation of amino
groups (Bhumkar and Pokharkar 2006). This leaves
negatively charged phosphoric ions, which have not been
utilized for neutralization of positive charge on chitosan,
to provide a net negative charge on to the particles. Ad-
sorption of the negatively charged phosphate ions on to
chitosan particles could be the underlying mechanism of
these particles bearing a negative charge. It has been
previously shown that negatively charged particles can be
taken up by the Caco-2 cells (Gaumet et al. 2009).
Therefore, the purpose of adding sodium alginate to
glycerol mono oleate chitosan nanoparticles was to
achieve crosslinking as well as changing surface charge so
that it can be taken up by the cells in the GI tract. The
drug loaded particles had a higher zeta potential. This
could be attributed to the free Ifosfamide adsorbed at the
surface of the particles. The secondary nitrogen attached
to the phosphorus atom of the phosphamide group in
Ifosfamide could be protonated to give it a net positive
charge, which causes an increase in the zeta potential of
drug loaded particles.
Figure 5 shows that the Ifosfamide NLC has smooth
spherical shaped appearance. The surface of formulated
nanoparticles depends on two factors: (a) a saturated so-
lution of polymer chitosan produced smooth and high
yield nanoparticles. The undissolved polymer produced
irregular and rod-shaped particles; (b) the diffusion rate of
solvent is too fast and the solvent may diffuse into the
aqueous phase before stable nanoparticles are developed
or formed causing the aggregation of nanoparticle prepa-
ration. In this preparation the polymer was completely
saturated and the diffusion rate of solvent was minimal
leading to the formation of smooth, spherical and indi-
vidually homogeneously distributed particles and has no
evidence of collapsed particles. Smooth surface reveals
complete removal of solvent from the formulated
nanoparticles.
FTIR spectroscopy
The sharp peak occurring at 1624 cm-1 indicates the
presence of sodium alginate, which shifts slightly to
1651 cm-1 and a peak appears at 1736 cm-1 indicating the
bending vibration of amino groups present in chitosan after
cross-linking to sodium alginate, A characteristic band
between 3500 and 3200 cm-1, which is due to O–H and N–
H stretching, was seen in chitosan. This band is further
intensified in the cross-linked particles due to interaction
between hydroxyl ions of sodium alginate and amino
groups of chitosan. This further confirms the cross-linking
of sodium alginate with chitosan in the formulation. The
cross linking between the sodium alginate and chitosan
molecule happens either by deprotonation or ionic cross
linking (Bhumkar and Pokharkar 2006). In the process of
deprotonation, there is a formation of hydrogen bonds be-
tween the positively charged amino groups of chitosan and
negatively charged hydroxyl groups donated by sodium
alginate. Thus, this extensive hydrogen bonding intensifies
the peak at 3500–3200 cm-1. A new peak appears in cross-
linked particles at 1113 cm-1, which could be attributed to
P=O bond that is derived from sodium alginate. Peaks at
2924 and 2876 cm-1 were observed, which denote C–H
stretching in alkanes. GMO is an ester of glycerol and oleic
acid. Oleic acid is a straight chain carboxylic acid com-
posed of 18 carbons. Furthermore, oleic acid present in the
formulation also had alkyl chains. C–H stretching in
alkanes is seen in the range of 3000–2850 cm-1. Thus, the
peaks at 2924 and 2876 cm-1 could be attributed to oleic
acid and GMO present in the formulation.
Comparing the FTIR spectra of pure polymer, lipid,
drug and formulation, we confirmed that there is no sig-
nificant interaction between drug and polymer and has
good chemical stability.
Differential scanning calorimetry
The endothermic peak of GMO at 30 C shifted to 26 C in
Ifosfamide-loaded NLCs. This shift might be due to for-
mation of nanoparticles with presence of drug (Ifosfamide
loaded NLCs). Reduced peak areas probably indicate a
reduction of lipid crystallinity in the NLCs, which should
be due to the lipid mixture (less solid lipid crystals). In case
of NLC, the nanoparticle matrix was composed of mixture
of lipids (solid and liquid lipids) instead of only solid lipid.
Although the mixture of solid and liquid lipids were solid
at room temperature, the chemical characteristics of the
mixture differs with that of the solid lipid when taken
alone. Either the liquid lipid was molecularly dispersed in
the solid lipid or the nanodroplets of the liquid lipid were
dispersed in the solid lipid. The absence of the detectable
crystalline endothermic peak of the Ifosfamide, GMO and
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sodium alginate in the formulation clearly indicated that
Ifosfamide, encapsulated in the nanoparticulate system,
was in the form of amorphous or in solid-state solubilized
form in the polymeric matrix (Fig. 7).
X-ray diffraction studies
In order to investigate the changes of the nanoparticle
crystalline structure, X-ray diffraction experiments were
performed. The X-ray diffraction patterns of ifosfamide,
blank NLCs and NLCs are displayed in Fig. 8. The
diffractogram of ifosfamide had two sharp peaks at
2h = 14.78, 15.16 and some peaks of lower intensity. On
the contrary, these sharp peaks disappeared from that of the
NLC formulation, indicating the amorphism of ifosfamide
in nanoparticles. Compared to physical mixture the peak
intensities of formulaton is weaker, suggesting that the
degree of the crystallinity is lower in the nanoparticle than
in the raw material. These results indicate that incorpora-
tion of ifosfamide to the lipid matrix leads to less ordered
crystals in NLC and confirms the deduction in DSC
analysis.
In vitro drug release
The in vitro release studies of Ifosfamide nanoparticles
were carried out at pH 1.2, 6.8 and 7.4 to correspond to
the pattern of release of Ifosfamide at the intestinal pH
(Fig. 9). The initial burst release in the delivery system
could be accounted for by any free or surface-bound drug.
To investigate the mechanism of drug release from the
delivery system, the cumulative drug release was plotted
against time. The linear nature of this plot indicates the
first-order release with the rate of drug release depending
on its concentration. At pH 1.2 and 6.8, Ifosfamide
showed a different release pattern compared with that
shown at pH 7.4. There was a reduction in the amount of
drug released. The quantity of drug released from the
nanoparticle at the pH 1.2 was found to be very low. In
the first 6 h, only 13 % of drug has been released, as
represented in Fig. 9a. Drug release experiment at the pH
6.8 shows 15 % drug release at the end of the sixth hour,
as represented in Fig. 9b. The delivery system showed an
initial burst release with approximately 62 % drug being
released at the end of 24 h. The release of Ifosfamide was
gradual thereafter with a plateau being reached after 72 h
(Fig. 9c). It is obvious that the decreased percentage of
drug release was due to the formation of a more compact
wall around the drug by the polymer and the strong cross-
linking of chitosan and sodium alginate that would lead to
reduction in diffusion of drug from the delivery system.
Percentage drug release of a pure drug candidate was
performed, and the release was 50 % at first hour and
almost 75 % was noted at the fourth hour, as represented
in Fig. 9d.
This reduction in the release of drug from the delivery
systems could be explained on the basis of interaction
between chitosan and sodium alginate. The stronger
crosslinking could lead to reduction in diffusion of drug
from the matrix and hence decrease in drug release.
Conclusion
A solvent diffusion method in an aqueous system was
employed to prepare the NLC. The Ifosfamide NLC was
optimized using the CCRD-RSM by fitting a quadratic
model to the response data. The experimental values of
the NLC prepared under the optimum conditions were
mostly close to the predicted values. Ifosfamide NLC
under the optimized conditions gave rise to the EE of
77 %, DL of 6.14 %, PS of *223 nm and ZP value of
-25 mV. TEM showed that the NLC particles are sphe-
rical, with drug loaded uniformly on the surface of and
inside the NLC. The drug release behavior from the NLC
exhibited a biphasic pattern with a burst release at the
initial stage and sustained release subsequently. The drug
release experiments in the NLC in vitro exhibited a sus-
tained release over 72 h. These results indicated that the
NLC obtained in this study could potentially be exploited
as a carrier with an initial dose and prolonged plasma
level in vivo. The proposed Ifosfamide NLC illustrates an
effective way to prolong a drug release. The developed
nanoparticles are safer and are the need of the hour for
pharmaceutical industry as an alternative drug delivery
system in chemotherapy.
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